EC359 |
Catalog No.GC39174 |
EC359 est un inhibiteur puissant, sélectif, de haute affinité et actif par voie orale du récepteur du facteur inhibiteur de la leucémie (LIFR) avec un Kd de 10,2 nM, qui interagit directement avec le LIFR pour bloquer efficacement les interactions LIF/LIFR.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2012591-09-0
Sample solution is provided at 25 µL, 10mM.
EC359 is a potent, selective, high affinity and orally active leukemia inhibitory factor receptor (LIFR) inhibitor with a Kd of 10.2 nM, which directly interacts with LIFR to effectively block LIF/LIFR interactions[1].
[1]. Viswanadhapalli S, et al. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 Aug;18(8):1341-1354.
Average Rating: 5
(Based on Reviews and 27 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *